Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H23NO.C4H6O6.2H2O |
Molecular Weight | 443.488 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=CC=C(O)C=C34
InChI
InChIKey=UMZNDVASJKIQCB-QLFXFZCRSA-N
InChI=1S/C17H23NO.C4H6O6.2H2O/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17;5-1(3(7)8)2(6)4(9)10;;/h5-6,11,14,16,19H,2-4,7-10H2,1H3;1-2,5-6H,(H,7,8)(H,9,10);2*1H2/t14-,16+,17+;1-,2-;;/m01../s1
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H6O6 |
Molecular Weight | 150.0868 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C17H23NO |
Molecular Weight | 257.3706 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Levorphanol, brand name Levo-Dromoran, is an opioid medication used to treat moderate to severe pain. Levorphanol is indicated for the management of moderate to severe pain where an opioid analgesic
is appropriate. It is a potent synthetic opioid mu-receptor agonist similar in action to morphine. Like other opioid
mu-receptor agonists, it is believed to act at receptors in both the brain and spinal cord to alter the transmission
and perception of pain. The onset and peak analgesic effects following administration of levorphanol are similar to
morphine when administered at equal analgesic doses. Levorphanol produces a degree of respiratory depression
similar to that produced by morphine at equal analgesic doses, and like many opioid mu-receptor agonists,
levorphanol produces euphoria or has a positive effect on mood in many individuals.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 |
0.21 nM [Ki] | ||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17039381 |
4.2 nM [Ki] | ||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17039381 |
2.3 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Levorphanol Tartrate Approved UseLevorphanol Tartrate Tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date1953 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator​
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 11.5 uM] | ||||
yes [IC50 >50 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Comparison of opioid agonists in maintaining responding and in suppressing morphine withdrawal in rhesus monkeys. | 1981 |
|
Prostaglandin hyperalgesia, V: a peripheral analgesic receptor for opiates. | 1982 Jan |
|
Relative cataleptic potency of narcotic analgesics, including 3,6-dibutanoylmorphine and 6-monoacetylmorphine. | 1984 |
|
Effect of prolyl-leucyl-glycinamide and alpha-melanocyte-stimulating hormone on levorphanol-induced analgesia, tolerance and dependence. | 1984 Jun 25 |
|
Baclofen-induced catatonia. | 1986 Dec |
|
Differential effects of morphinan drugs on haloperidol-induced catalepsy in rats: a comparative study with an N-methyl-D-aspartate antagonist. | 1991 Mar-Apr |
|
Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. | 1995 Sep |
|
Age-related differences in sensitivity to the antinociceptive effects of opioids in male rats. Influence of nociceptive intensity and intrinsic efficacy at the mu receptor. | 2001 Aug |
|
Central discriminative effects of morphine in rats: training via intracerebroventricular administration. | 2001 Dec |
|
The safety of dextromethorphan in pregnancy : results of a controlled study. | 2001 Feb |
|
Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. | 2002 Apr |
|
Interface for coupling nonaqueous wide-bore capillary electrophoresis with mass spectrometry. | 2002 Feb |
|
Clinical pharmacology of opioids for pain. | 2002 Jul-Aug |
|
Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats. | 2002 Nov 29 |
|
Sex-related differences in mechanical nociception and antinociception produced by mu- and kappa-opioid receptor agonists in rats. | 2002 Oct 4 |
|
Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cyclase superactivation is independent of agonist-induced phosphorylation, desensitization, internalization, and down-regulation. | 2003 Dec |
|
The power of visual imagery in drug design. Isopavines as a new class of morphinomimetics and their human opioid receptor binding activity. | 2003 Jan 2 |
|
Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence. | 2003 Mar |
|
Opioids ease neuropathic pain, but.. | 2003 May |
|
Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey. | 2003 May |
|
Differential regulation of the human kappa opioid receptor by agonists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and phosphorylation. | 2003 May |
|
10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors. | 2004 Jan 1 |
|
Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. | 2004 May |
|
Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates. | 2004 Sep |
|
[Fundamentals of modern treatment of myopia]. | 2005 |
|
Social and environmental influences on opioid sensitivity in rats: importance of an opioid's relative efficacy at the mu-receptor. | 2005 Aug |
|
Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. | 2005 Jul |
|
Discriminative stimulus effects of acute morphine followed by naltrexone in the squirrel monkey: a further characterization. | 2005 Jul |
|
Over-the-counter cold medications-postmortem findings in infants and the relationship to cause of death. | 2005 Oct |
|
Chronic exercise decreases sensitivity to mu opioids in female rats: correlation with exercise output. | 2006 Sep |
|
Can levorphanol be used like methadone for intractable refractory pain? | 2007 Apr |
|
Cholesterol reduction by methyl-beta-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cells. | 2007 Feb 15 |
|
Levorphanol: the forgotten opioid. | 2007 Mar |
|
Opiates and elderly: use and side effects. | 2008 |
|
Challenges in using opioids to treat pain in persons with substance use disorders. | 2008 Jun |
|
A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. | 2009 Jun 30 |
|
Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells. | 2009 Jun 7 |
|
Chronic pain: levorphanol, methadone, and the N-methyl-D-aspartate receptor. | 2009 Sep |
|
Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan. | 2010 Jan |
|
Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. | 2010 Jan 14 |
|
Acute pain management in children. | 2010 Jul 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/levorphanol.html
Usual Adult Dose for Light Sedation
Premedication for Anesthesia:
1 to 2 mg IM or subcutaneously, administered 60 to 90 minutes before surgery. Older or debilitated patients usually require less drug. Two mg of levorphanol is approximately equivalent to 10 to 15 mg of morphine or 100 mg of meperidine.
Usual Adult Dose for Pain
IV: 1 mg every 3 to 6 hours as needed.
IM or subcutaneous: 1 to 2 mg every 6 to 8 hours as needed.
Oral: 2 mg every 6 to 8 hours as needed.
May be increased to 3 mg every 6 to 8 hours.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7284815
Levorphanol (5-100 uM), consistently depressed the responses evoked by the putative inhibitory amino acid neurotransmitters glycine and beta-alanine but not GABA in cultured mouse spinal cord neurons.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:01:23 GMT 2025
by
admin
on
Mon Mar 31 18:01:23 GMT 2025
|
Record UNII |
04WQU6T9QI
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1506
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5985-38-6
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | |||
|
m6794
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID30975252
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | |||
|
DBSALT000935
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | |||
|
04WQU6T9QI
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | |||
|
6700-40-9
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
SUPERSEDED | |||
|
04WQU6T9QI
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | |||
|
153973
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | RxNorm | ||
|
5985-51-3
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
SUPERSEDED | |||
|
5462348
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | |||
|
C47586
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | |||
|
1364007
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | |||
|
SUB02914MIG
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY | |||
|
CHEMBL592
Created by
admin on Mon Mar 31 18:01:23 GMT 2025 , Edited by admin on Mon Mar 31 18:01:23 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |